Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 5,404 matching trials from the live ClinicalTrials.gov search.

Filters: Tucson, Arizona Clear all

Conditions: Head &Amp; Neck Cancer, Head &Amp; Neck Squamous Cell Carcinoma
Interventions: Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF); Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 12
States / cities: Tucson, Arizona • Irvine, California • Orange, California + 9 more

Conditions: Cystic Fibrosis, Lung Infection, Pseudomonas Aeruginosa
Interventions: AZLI 75 mg three times daily (TID), Placebo three times daily (TID); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 6 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 34
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 26 more

Conditions: Influenza, Myxovirus Infection
Interventions: Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1), Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2), Split, Inactivated, Trivalent Influenza Vaccine (Standard dose), Split, Inactivated, Trivalent Influenza Vaccine (High-dose); Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 2,098 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 29
States / cities: Alabaster, Alabama • Mobile, Alabama • Chandler, Arizona + 26 more

Conditions: Colorectal Cancer
Interventions: Napabucasin, Fluorouracil, Leucovorin, Irinotecan, Bevacizumab; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more

Conditions: Congestive Heart Failure
Interventions: Tolvaptan; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 161
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 131 more

Conditions: Parkinson's Disease, Levodopa Induced Dyskinesias (LID)
Interventions: 240mg Amantadine HCl ER tablets, Placebo tablets, 320mg Amantadine HCl ER tablets; Drug
Lead sponsor: Adamas Pharmaceuticals, Inc.; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 26
States / cities: Tucson, Arizona • Fountain Valley, California • Irvine, California + 21 more

Conditions: Neurotrophic Keratopathy
Interventions: MR-146; Genetic
Lead sponsor: Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 11
States / cities: Sun City, Arizona • Tucson, Arizona • Glendale, California + 8 more

Conditions: Atrial Fibrillation
Interventions: Azimilide Dihydrochloride, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 69
States / cities: Mobile, Alabama • Tucson, Arizona • Burlingame, California + 63 more

Conditions: Advanced Non-Small Cell Lung Cancer
Interventions: Pemetrexed, Carboplatin, Paclitaxel, Bevacizumab; Drug · Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 45
States / cities: Scottsdale, Arizona • Tucson, Arizona • Mission Hills, California + 42 more

Conditions: Major Depressive Disorder
Interventions: ALKS 5461, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 27
States / cities: Tucson, Arizona • Oceanside, California • Santa Ana, California + 24 more

Conditions: Eosinophilic Esophagitis
Interventions: Reslizumab, Saline; Biological · Other
Lead sponsor: Ception Therapeutics; Industry
Eligibility: 5 Years to 18 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 34
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more

Conditions: Systemic Lupus Erythematosus
Interventions: Anifrolumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 32
States / cities: Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 25 more

Conditions: Influenza
Interventions: MK-1406, Placebo; Combination Product
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 12 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 135
States / cities: Anniston, Alabama • Cullman, Alabama • Glendale, Arizona + 116 more

Conditions: Ventricular Ejection Fraction
Interventions: Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 10
States / cities: Tucson, Arizona • Chicago, Illinois • Washington DC, Maryland + 7 more

Conditions: Crohn's Disease
Interventions: GSK1605786A; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 55
States / cities: Little Rock, Arizona • Tucson, Arizona • Anaheim, California + 49 more

Conditions: Pulmonary Arterial Hypertension
Interventions: ACT-293987; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 709 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 45
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more

Conditions: Concussion, Mild, Post-Concussion Symptoms, Sleep Problems
Interventions: wavelength-1 bright light, wavelength-2 bright light; Device
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Arthritis, Osteoarthritis
Interventions: tanezumab 10 mg, tanezumab 5 mg, naproxen, placebo; Biological · Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 832 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 94
States / cities: Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 72 more

Conditions: Age-Related Macular Degeneration
Interventions: E10030, ranibizumab, E10030 sham intravitreal injection; Drug
Lead sponsor: Ophthotech Corporation; Industry
Eligibility: 50 Years and older
Enrollment: 627 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 49
States / cities: Tucson, Arizona • Fresno, California • La Jolla, California + 43 more

Conditions: Lymphoma
Interventions: cisplatin, etoposide, gemcitabine, methylprednisolone; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 77
States / cities: Tucson, Arizona • Little Rock, Arkansas • Fremont, California + 54 more

Conditions: Colostomy
Interventions: One piece closed pouch; Device
Lead sponsor: ConvaTec Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Invasive Fungal Infection
Interventions: Isavuconazonium sulfate, Voriconazole, Posaconazole; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: Not listed
Enrollment: 2,015 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 56
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more

Conditions: Gastroesophageal Reflux
Interventions: Dexlansoprazole, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 43
States / cities: Tucson, Arizona • Anaheim, California • Garden Grove, California + 40 more

Conditions: Short Sleep Duration
Interventions: Sleep Diary, Fitbit; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 60 Years
Enrollment: 1,038 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tucson, Arizona

Search by objective public record fields.

Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa

Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects

A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer

EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan

Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.

A Phase 1/2, Single-Dose, Multicenter, Dose Escalation, Clinical Trial to Evaluate the Safety and Efficacy of MR-146: An Open-Label Part 1 in Participants With Stage 1 or 2 Neurotrophic Keratopathy and a Double-Masked Part 2 in Participants With Stage 2 Neurotrophic Keratopathy

Efficacy and Safety of Azimilide for the Treatment of Patients With Atrial Fibrillation

Study of Participants With Advanced Non-Small Cell Lung Cancer

A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)

Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)

DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function

Open-Label Extension Study of GSK1605786A

ACT-293987 in Pulmonary Arterial Hypertension

Effects of Bright Light Therapy in Mild Traumatic Brain Injury

Tanezumab In Osteoarthritis Of The Knee (2)

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

One Piece Closed Pouch in Subjects With a Colostomy

Registry of Patients Treated With Systemic Mold-Active Triazoles

A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn

Hypknowledge Nationwide Sleep Extension